Rigshospitalet, Denmark — Biomedical Watch V2

Traitements8programmes

Essais5liés

Publications2liées

SourceDBlocale

Traitements

8

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
3 Year Follow up on ANO5 PatientsThe aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to: 1. investigate possible progression of disease over time 2. investigate good and reliable outcome measures	Myopathies	À vérifier	Ralentissement de la progression	Denmark	À vérifier
ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 VariantsA large cohort of MRI scans from patients with pathogenic variants in the anoctamin 5 gene will be collected through an international collaboration to better describe muscle involvement.	Myopathies	À vérifier	À vérifier	Denmark	À vérifier
FexofenadineThe DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.	SEP	Phase 3	À vérifier	Denmark	À vérifier
ParacetamolThe DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.	SEP	Phase 3	À vérifier	Denmark	À vérifier
Physical Activity and Fatigue in Myasthenia GravisDanish patients with myasthenia gravis are asked to answer a validated and international questionnaire about physical activity. Also background questions about their disease and comorbidity are asked. To validate the data about physical activity from the questionnaires 69 patients are asked to wear an accelerometer for 7 days to measure activity level.	Myasthénie	À vérifier	Traitement symptomatique	Denmark	À vérifier
Physical Activity and Fatigue in Myasthenia GravisDanish patients with myasthenia gravis are asked to answer a validated and international questionnaire about physical activity. Also background questions about their disease and comorbidity are asked. To validate the data about physical activity from the questionnaires 69 patients are asked to wear an accelerometer for 7 days to measure activity level.	Myasthénie	À vérifier	Traitement symptomatique	Denmark	À vérifier
ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 VariantsA large cohort of MRI scans from patients with pathogenic variants in the anoctamin 5 gene will be collected through an international collaboration to better describe muscle involvement.	Myopathies	À vérifier	À vérifier	Denmark	À vérifier
3 Year Follow up on ANO5 PatientsThe aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to: 1. investigate possible progression of disease over time 2. investigate good and reliable outcome measures	Myopathies	À vérifier	Ralentissement de la progression	Denmark	À vérifier

Essais cliniques

5

Molécule	Indication / population	Phase	NCT	Titre	Statut
Rituximab	SEP	Phase 3	NCT04688788	DanNORMS — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	ACTIVE_NOT_RECRUITING
3 Year Follow up on ANO5 Patients	Myopathies	À vérifier	NCT05206617	3 Year Follow up on ANO5 Patients	ACTIVE_NOT_RECRUITING
ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	Myopathies	À vérifier	NCT05102799	ANO5 MRI — MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	ACTIVE_NOT_RECRUITING
Physical Activity and Fatigue in Myasthenia Gravis	Myasthénie	À vérifier	NCT03905473	Physical Activity and Fatigue in Myasthenia Gravis	COMPLETED
Sildenafil	Myopathies	Phase 2	NCT01350154	Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients	COMPLETED

Publications

2

Molécule	Indication / population	Titre	Journal	Date
3 Year Follow up on ANO5 Patients		Clinical and genetic features of anoctaminopathy in Saudi Arabia.	Neurosciences (Riyadh, Saudi Arabia)
3 Year Follow up on ANO5 Patients		A hospital based epidemiological study of genetically determined muscle disease in south western Norway.	Neuromuscular disorders : NMD